Clinical trial
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With…
NCT00481325 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00481325 |
|---|---|
| Title | Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Anxiety Disorder |
| Intervention type | Drug |
| Interventions | pexacerfont, escitalopram, placebo |
| Enrollment | 260 |
| Start date | Jul 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jun 1, 2007 |
| Last update posted | Oct 12, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: